Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

The Role of the GP in the Management of Ambulatory Heart Failure (GPsHF)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05056649
Recruitment Status : Not yet recruiting
First Posted : September 24, 2021
Last Update Posted : September 24, 2021
Sponsor:
Information provided by (Responsible Party):
Jean-Marc BOIVIN, Central Hospital, Nancy, France

Brief Summary:
To describe the causes mentioned by general practitioners, explaining the under-treatment of the three main treatments for heart failure with impaired ejection fraction (ARS blockers of the type ACEinhibitor/ARA2/ARNi, ß- and/or anti-aldosterone).

Condition or disease
Heart Failure

Layout table for study information
Study Type : Observational
Estimated Enrollment : 300 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: The Role of the GP in the Management of Ambulatory Heart Failure
Estimated Study Start Date : October 1, 2021
Estimated Primary Completion Date : June 1, 2022
Estimated Study Completion Date : June 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Group/Cohort
Heart Failure Patients with impaired ejection fraction



Primary Outcome Measures :
  1. Quantitative analysis of verbatims after grouping [ Time Frame: Through study completion, an average of 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Heart failure patients with impaired ejection fraction (LVEF < 40%), under 85 years of age, admitted to the emergency department for cardiac decompensation and hospitalised in the aftermath of this decompensation, for whom the sum of the doses of ACE inhibitor or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient
Criteria

Inclusion Criteria:

  • Patients with a previous diagnosis of heart failure with impaired ejection fraction (LVEF < 40%)
  • Under 85 years of age
  • Admitted to an Emergency department for cardiac decompensation
  • Hospitalized following this decompensation
  • Not deceased within one month of hospitalisation
  • Whose sum of the doses of ACEI or ARB2 + BB + aldosterone antagonist is less than 50% of the dose required for this patient* (definition in annex)
  • Who did not object within one month of being informed

Exclusion Criteria:- Patient objecting to the use of their data

  • Patient who is a minor
  • Patient who does not have a general practitioner

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05056649


Contacts
Layout table for location contacts
Contact: Jean-Marc BOIVIN, MD,PhD 3 83 15 73 11 ext 33 jm.boivin@chru-nancy.fr
Contact: Nicolas GIRERD, MD, PhD 383 5 7322 ext 33 n.girerd@chru-nancy.fr

Locations
Layout table for location information
France
CHRU of Nancy
Vandœuvre-lès-Nancy, France, 54500
Contact: Jean-Marc BOIVIN, MD, PhD         
Principal Investigator: Jean-Marc BOIVIN, MD, PhD         
Sponsors and Collaborators
Jean-Marc BOIVIN
Layout table for additonal information
Responsible Party: Jean-Marc BOIVIN, Professor, Central Hospital, Nancy, France
ClinicalTrials.gov Identifier: NCT05056649    
Other Study ID Numbers: 2020PI049
First Posted: September 24, 2021    Key Record Dates
Last Update Posted: September 24, 2021
Last Verified: September 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Diseases
Cardiovascular Diseases